Semaglutide is a GLP-1 receptor agonist that slows digestion and reduces appetite by mimicking one gut hormone. It is FDA-approved as Ozempic for type 2 diabetes and Wegovy for chronic weight management.

Retatrutide is a triple agonist that activates GLP-1, GIP, and glucagon receptors. The added glucagon activation may boost fat burning and metabolic rate. It is not yet FDA-approved and is still in clinical trials.

Semaglutide vs Retatrutide: Which Cuts More Weight?

Q: Can semaglutide and retatrutide be taken together?

No. Both activate overlapping GLP-1 receptors. Combining them offers no added benefit and may increase side effects. Use only one at a time.

Built by medical professionals, gym rats, and experienced biohackers

Retatrutide may cut more weight based on early data, but semaglutide is the one you can actually get right now. Retatrutide is not FDA-approved yet.

Which Weight-Loss Drug Should You Focus On?

Semaglutide (Ozempic, Wegovy) targets one gut hormone receptor. It is FDA-approved and has years of real-world use behind it. Retatrutide targets three hormone receptors and is still in Phase 3 trials. Early data suggests it may produce greater weight loss than semaglutide . It is not available by prescription today.

What Is Semaglutide?

Semaglutide is a GLP-1 receptor agonist. It copies a hormone called GLP-1, which slows how fast your stomach empties and signals your brain to feel full.

It is FDA-approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy). The STEP trials showed average body weight reductions of roughly 15% over 68 weeks .

It is injected once a week and titrated up gradually over several months.

What Is Retatrutide?

Retatrutide is a triple agonist: it activates GLP-1, GIP, and glucagon receptors.

The first two (GLP-1 and GIP) suppress appetite and slow digestion, similar to semaglutide and tirzepatide. The third (glucagon) is different. Glucagon tells the liver to burn stored energy and raises the body's metabolic rate. This extra target may explain why Phase 2 data showed higher-than-expected weight loss .

Retatrutide is not FDA-approved. As of mid-2026, it is in Phase 3 trials .

How Do They Differ?

Feature	Semaglutide	Retatrutide
Receptor targets	GLP-1 only	GLP-1, GIP, and glucagon
FDA approval	Yes (Ozempic, Wegovy)	No (Phase 3 trials)
Availability	Prescription from a doctor	Clinical trials only
Typical dose	Up to 2.4 mg weekly	Up to 12 mg weekly in trials
Average weight loss seen	Roughly 15% of body weight	Up to 24% in Phase 2
Evidence level	Large completed Phase 3 trials, post-market data	Phase 2 complete; Phase 3 pending
Years in clinical use	Since 2017	Not yet in general use

Mechanism gap. The most important difference between semaglutide and retatrutide is the glucagon receptor. Semaglutide slows digestion and reduces appetite. Retatrutide does both of those things. It also activates a pathway that may actively increase energy burning . That third action makes retatrutide a different class of drug. It is not just a stronger version of semaglutide.

Trial comparisons. The STEP trials for semaglutide and the Phase 2 retatrutide trials used different designs and patient groups. They cannot be compared head to head directly. What can be said is that retatrutide's early numbers are higher. Phase 3 results will provide a cleaner picture .

Side effects. Semaglutide's GI side effect profile is well documented from years of post-market use. Nausea, vomiting, and constipation are the most common . Retatrutide's full side effect profile is still being studied in trials.

Can You Take Both Together?

No. Both drugs activate GLP-1 receptors. Taking them together offers no synergy and may increase unwanted side effects. Only one should be used at a time.

How Do You Track a Long Weight-Loss Protocol?

Weight-loss drugs involve months of gradual dose increases. People on structured protocols track their dose, weight, and how they feel so they can adjust with their doctor. DoseVault makes that kind of ongoing log simple and organized.

Frequently Asked Questions

What is semaglutide?
Semaglutide is a GLP-1 receptor agonist that slows digestion and reduces appetite. It is FDA-approved as Ozempic and Wegovy.

What is retatrutide?
Retatrutide is a triple agonist (GLP-1, GIP, glucagon) still in Phase 3 clinical trials and not yet approved.

Which drug causes more weight loss?
Retatrutide's Phase 2 data showed higher average weight loss than semaglutide's STEP trials. Direct comparison is limited by different study designs .

Can semaglutide and retatrutide be taken together?
No. They share the GLP-1 receptor and should not be combined.

Which Do People Pick, and When?

This is general guidance, not personalized medical advice. Both drugs require a licensed clinician's involvement.

Choose semaglutide if:
- You want an FDA-approved option with a long track record
- Your insurance or budget supports it
- You are starting a weight-loss drug for the first time

Watch retatrutide if:
- You want to follow what may be the next generation of weight-loss drugs
- You have maxed out results on semaglutide and want to know what is coming
- You are interested in clinical trial participation

This page is educational only. It is not medical advice and does not replace consultation with a licensed healthcare provider. Prescription drugs require a doctor's supervision. Do not use these drugs to diagnose, treat, cure, or prevent any condition.

Built by medical professionals, gym rats, and experienced biohackers

Running a weekly drug protocol? DoseVault helps you track your dose titration, log how you feel each week, and keep your full protocol history in one place.